580 related articles for article (PubMed ID: 36151309)
1. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; Aroda VR; Collins BS; Gabbay RA; Green J; Maruthur NM; Rosas SE; Del Prato S; Mathieu C; Mingrone G; Rossing P; Tankova T; Tsapas A; Buse JB
Diabetologia; 2022 Dec; 65(12):1925-1966. PubMed ID: 36151309
[TBL] [Abstract][Full Text] [Related]
2. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; Aroda VR; Collins BS; Gabbay RA; Green J; Maruthur NM; Rosas SE; Del Prato S; Mathieu C; Mingrone G; Rossing P; Tankova T; Tsapas A; Buse JB
Diabetes Care; 2022 Nov; 45(11):2753-2786. PubMed ID: 36148880
[TBL] [Abstract][Full Text] [Related]
3. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
[TBL] [Abstract][Full Text] [Related]
4. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
Diabetologia; 2020 Feb; 63(2):221-228. PubMed ID: 31853556
[TBL] [Abstract][Full Text] [Related]
5. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
Diabetes Care; 2018 Dec; 41(12):2669-2701. PubMed ID: 30291106
[TBL] [Abstract][Full Text] [Related]
6. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
[TBL] [Abstract][Full Text] [Related]
7. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
Diabetes Care; 2020 Feb; 43(2):487-493. PubMed ID: 31857443
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of type 2 diabetes - Recommendations of the European Association for the Study of Diabetes (EASD)].
Müller-Wieland D; Marx N
Dtsch Med Wochenschr; 2020 May; 145(9):593-600. PubMed ID: 32349146
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
[TBL] [Abstract][Full Text] [Related]
11. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G
Kidney Int; 2022 Nov; 102(5):974-989. PubMed ID: 36202661
[TBL] [Abstract][Full Text] [Related]
12. Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.
Wisniewski B; Smith E; Kaur J; Sherling C; Vanapalli S; Lussier M
J Manag Care Spec Pharm; 2024 Jan; 30(1):34-42. PubMed ID: 38153863
[TBL] [Abstract][Full Text] [Related]
13. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis.
Ali MU; Mancini GBJ; Fitzpatrick-Lewis D; Connelly KA; O'Meara E; Zieroth S; Sherifali D
Cardiovasc Diabetol; 2024 Feb; 23(1):72. PubMed ID: 38360604
[TBL] [Abstract][Full Text] [Related]
16. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Powell JR; Wittwer JA; Chu JX; Sewell KA; Wu Q; Cummings DM
Diabetes Obes Metab; 2019 Oct; 21(10):2274-2283. PubMed ID: 31168889
[TBL] [Abstract][Full Text] [Related]
17. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
18. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
Scheen AJ
Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
[TBL] [Abstract][Full Text] [Related]
19. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
[TBL] [Abstract][Full Text] [Related]
20. Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care.
Colling C; Atlas SJ; Wexler DJ
Diabetes Care; 2021 Jun; 44(6):1443-1446. PubMed ID: 34016618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
